IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare kidney diseases: sparsentan trial aims to cut protein leakage
Disease control Recruiting nowThis study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein in the urine. The goal is to see if the drug safely reduces protein leakage and helps control the disease over about two years. Participants take the drug once daily, an…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:46 UTC
-
New antibody drug aims to control kidney disease
Disease control Recruiting nowThis study tests a new drug called MIL116 in healthy people and those with IgA nephropathy, a kidney disease. The goal is to see if it is safe and can help control the disease by reducing harmful proteins. About 130 participants will take part in this early-phase trial.
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for kidney disease: drug trial targets protein leak to save kidney function
Disease control Recruiting nowThis phase 3 study tests whether ravulizumab can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either the drug or a placebo. The goal is to see if the drug sl…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, which is a sign of kidney damage. Participants receive the drug through an IV and are monitored for sa…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New drug iptacopan under microscope in kidney biopsy study
Knowledge-focused Recruiting nowThis study looks at how the drug iptacopan affects the kidneys of 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to measure changes in immune system activity and kidney damage over 9 months. The goal is to understand how iptac…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC